经皮肾肿瘤消融术后超声造影的临床应用
纳入31例接受经皮射频消融的肾肿瘤患者,术后行超声造影并与增强CT/MRI对比。消融区大于原发肿瘤时完全消融率更高(p=0.026)。超声造影评估完全消融的敏感度88.9%、特异度100%、阳性预测值100%、阴性预测值95.7%,评估肿瘤复发的敏感度和特异度均为100%。
要点
- 消融区大于原发肿瘤时完全消融率更高(p=0.026)。
- 超声造影评估完全消融的敏感度88.9%、特异度100%、阳性预测值100%、阴性预测值95.7%。
- 超声造影评估肿瘤复发的敏感度和特异度均为100%。
核心结论
- 经皮肾肿瘤射频消融术后,超声造影在随访评估残留和复发肿瘤方面的效果与增强CT/MRI基本相同。
研究设计与样本
- 31例患者纳入射频消融治疗,术后行超声造影检查,观察消融区及消融区内造影剂分布,并与增强CT/MRI图像对比以判断肾肿瘤残留和局部复发。
关键影像表现/征象
- 首次射频消融后肿瘤平均最大直径为32.3 ± 14.7 mm,消融区平均最大直径为35.9 ± 12.2 mm。
诊断标准与关键数值
- 超声造影评估肾肿瘤完全消融的敏感度88.9%、特异度100%、阳性预测值100%、阴性预测值95.7%。
- 超声造影评估肿瘤复发的敏感度和特异度均为100%。
- 射频消融后1个月内,增强CT/MRI显示31例中9例(29.0%)不完全消融,超声造影显示31例中8例(25.8%)不完全消融。
- 随访期间,27例完全消融患者中2例(7.4%)报告局部复发,两例的肿瘤复发征象均被超声造影和增强CT/MRI识别。
临床应用与阅片要点
- 经皮肾肿瘤射频消融术后,超声造影在随访评估残留和复发肿瘤方面的效果与增强CT/MRI基本相同。
- 联合多种随访方法可能提高残留或复发肿瘤的检出率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effectiveness of contrast-enhanced ultrasound (CEUS) in detecting incomplete ablation and local recurrence of renal tumors after percutaneous radiofrequency ablation (RFA).
METHODS: 31 patients were included for RFA treatment and underwent CEUS examination after RFA, ablation zone and contrast distribution in the ablation area were observed, CEUS images were compared with enhanced CT/MRI images to determine the residual tumors and local recurrence of renal tumors.
RESULTS: The average maximum diameters of the tumor and the ablation zone after the first RFA were 32.3 ± 14.7 mm and 35.9 ± 12.2 mm, respectively. A higher rate of complete tumor ablation was achieved if the ablation zone was larger than the primary tumor (p = 0.026). Within 1 month after RFA, contrast-enhanced CT/MRI examinations demonstrated incomplete ablation in 9 of 31 patients (29.0%), while CEUS revealed incomplete ablation in 8 of 31 patients (25.8%). The sensitivity, specificity, positive predictive value and negative predictive value of CEUS in evaluating complete ablation of renal tumors were 88.9%, 100%, 100%, 95.7%, respectively. During the follow-up period, local recurrence was reported in 2 (7.4%) of the 27 patients with complete tumor ablation. Tumor recurrence signs in the two patients were identified by both CEUS and contrast-enhanced CT/MRI. Therefore, both the sensitivity and specificity of CEUS for the evaluation of tumor recurrence were 100%.
CONCLUSION: After percutaneous RFA of renal tumors, the effectiveness of CEUS in the follow-up assessment of residual and recurrent tumors is basically the same as that of contrast-enhanced CT/MRI.
ADVANCES IN KNOWLEDGE: In this study, we evaluated the effectiveness of CEUS in the follow-up assessment of residual and recurrent tumors after RFA is basically the same as that of contrast-enhanced CT/MRI. Combining multiple follow-up methods may improve the detection rate of residual or recurrent tumors.
引用
- Guo F, Hu B, Chen L, et al. Clinical application of contrast-enhanced ultrasound after percutaneous renal tumor ablation. Br J Radiol. 2019. PMID: 31509441. doi:10.1259/bjr.20190183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。